Enanta Pharmaceutica (ENTA) 22.02 $ENTA
Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
BusinessWire - Mon Aug 29, 7:30AM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a business overview and an update on Enanta's research and development pipeline at each of the following investor conferences:
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2016
BusinessWire - Mon Aug 08, 3:01PM CDT
--Royalty revenue was $14.0 million
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus
BusinessWire - Mon Jun 20, 6:00AM CDT
--New non-DAA mechanism retains potency against important DAA resistance-associated variants (RAVs), regardless of class
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2016
BusinessWire - Mon May 09, 3:02PM CDT
--Royalty revenue from paritaprevir-containing regimens was $13.0 million
ENTA: 22.02 (+0.03)
Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:19AM CDT
However, a few companies are still yet to report quarterly numbers. Let's see what we can expect from a few drug stocks reporting earnings early next week.
BIIB: 306.03 (+0.40), ABT: 42.30 (+0.28), JNJ: 119.08 (-0.26), FLML: 13.87 (+0.50), IRWD: 13.35 (+0.01), GILD: 77.42 (-0.96), AMGN: 170.13 (+0.07), FGEN: 17.33 (+0.02), ENTA: 22.02 (+0.03), NVS: 78.27 (-0.50)
Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2016
BusinessWire - Wed Apr 27, 3:05PM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2016 after the U.S. markets close on May 9, 2016. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's research and development pipeline.
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals to Present at the Deutsche Bank 41st Annual Healthcare Conference Presentation to be Webcast on May 4, 2016 at 8:00 A.M. ET
BusinessWire - Tue Apr 26, 7:00AM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal presentation session to investors at the Deutsche Bank 41st Annual Healthcare Conference on May 4, 2016 at 8:00 a.m. ET.
ENTA: 22.02 (+0.03)
Enanta Announces U.S. FDA has Approved AbbVie's Supplemental New Drug Application for Use of VIEKIRA PAK(R) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
BusinessWire - Mon Apr 25, 8:10AM CDT
--Supplemental New Drug Application was previously granted priority review designation by the FDA
ENTA: 22.02 (+0.03)
AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
PR Newswire - Mon Apr 25, 8:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the use of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without ribavirin (RBV) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection and compensated cirrhosis (Child-Pugh A). The application was previously granted priority review by the FDA, a designation given to investigational therapies that treat a serious condition and provide a significant improvement in safety or effectiveness.
ABBV: 64.03 (-0.07), ENTA: 22.02 (+0.03)
Enanta Announces New Data from AbbVie's SURVEYOR-1 and SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates after 8 or 12 Weeks of Treatment in Patients with any of Genotypes 1 through 6 of Hepatitis C Virus
BusinessWire - Sat Apr 16, 12:10AM CDT
--100 percent SVR12 achieved with 12 weeks of treatment in difficult-to-treat genotype 3 patients with compensated cirrhosis (Child-Pugh A) new to therapy (3)
ENTA: 22.02 (+0.03)
Enanta Announces that AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
BusinessWire - Fri Apr 15, 12:15AM CDT
--91 percent achieved SVR12 with RBV in the primary intent-to-treat analysis; 86 percent achieved SVR12 without RBV
ENTA: 22.02 (+0.03)
AbbVie Announces Real-World Data with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) from Large German Hepatitis C-Registry
PR Newswire - Fri Apr 15, 12:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12).1 These data support results seen in Phase 3 clinical trials for chronic GT1 or GT4 hepatitis C virus (HCV) infected patients treated with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) with or without ribavirin (RBV).
ABBV: 64.03 (-0.07), ENTA: 22.02 (+0.03)
AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
PR Newswire - Fri Apr 15, 12:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis. Additionally, 86 percent (n=19/22) of GT1 patients who received ABT-493 and ABT-530 without RBV, achieved SVR12.1 SVR12 was achieved in 95 percent of patients with and without RBV (n=20/21, n=19/20; respectively) in a modified intent-to-treat analysis, excluding patients who did not achieve SVR for reasons other than virologic failure.
ABBV: 64.03 (-0.07), ENTA: 22.02 (+0.03)
Enanta Announces High SVR Rates with AbbVie's VIEKIRAX(R) + EXVIERA(R) Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients
BusinessWire - Thu Apr 14, 7:22PM CDT
--97 percent of genotype 1a (GT1a) patients, with or without baseline NS5A RAVs, who received the regimen with ribavirin achieved SVR12(1)
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals Announces HCV Data Presentations at The International Liver Congress(TM) 2016
BusinessWire - Wed Mar 30, 6:07AM CDT
--New data to be presented on AbbVie's investigational, pan-genotypic regimen consisting of ABT-493, Enanta's second protease inhibitor, in combination with ABT-530, AbbVie's NS5A inhibitor
ENTA: 22.02 (+0.03)
AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress(TM) 2016
PR Newswire - Wed Mar 30, 6:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for presentation at The International Liver Congress(TM) (ILC) 2016 in Barcelona, Spain, April 13-17, including real-world data that support clinical trial results seen in AbbVie's development program with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets). Abstracts presented will further expand scientific knowledge of VIEKIRAX and EXVIERA in genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infected patients, including those with compensated cirrhosis (Child-Pugh A).
ABBV: 64.03 (-0.07), ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals beats 1Q profit forecasts
Automated Insights - Mon Feb 08, 3:14PM CST
WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Monday reported fiscal first-quarter earnings of $26.2 million.
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
BusinessWire - Mon Feb 08, 3:02PM CST
--Royalty revenue for paritaprevir containing regimens was $17.9 million
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals to Present at Two Upcoming Investor Conferences
BusinessWire - Mon Aug 29, 7:30AM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will present a business overview and an update on Enanta's research and development pipeline at each of the following investor conferences:
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2016
BusinessWire - Mon Aug 08, 3:01PM CDT
--Royalty revenue was $14.0 million
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals Initiates Proof-of-Concept Study with Pan-genotypic Cyclophilin Inhibitor EDP-494 in Patients with Genotype 1 or Genotype 3 Chronic Hepatitis C Virus
BusinessWire - Mon Jun 20, 6:00AM CDT
--New non-DAA mechanism retains potency against important DAA resistance-associated variants (RAVs), regardless of class
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2016
BusinessWire - Mon May 09, 3:02PM CDT
--Royalty revenue from paritaprevir-containing regimens was $13.0 million
ENTA: 22.02 (+0.03)
Drug Stocks' Earnings Previews: FGEN, IRWD, ENTA, FLML
Zacks Equity Research - Zacks Investment Research - Fri May 06, 9:19AM CDT
However, a few companies are still yet to report quarterly numbers. Let's see what we can expect from a few drug stocks reporting earnings early next week.
BIIB: 306.03 (+0.40), ABT: 42.30 (+0.28), JNJ: 119.08 (-0.26), FLML: 13.87 (+0.50), IRWD: 13.35 (+0.01), GILD: 77.42 (-0.96), AMGN: 170.13 (+0.07), FGEN: 17.33 (+0.02), ENTA: 22.02 (+0.03), NVS: 78.27 (-0.50)
Enanta Pharmaceuticals to Host Conference Call on May 9 at 4:30 p.m. ET to Discuss Financial Results for its Fiscal Second Quarter Ended March 31, 2016
BusinessWire - Wed Apr 27, 3:05PM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that it plans to report its financial results for its fiscal second quarter ended March 31, 2016 after the U.S. markets close on May 9, 2016. Enanta management will host a conference call at 4:30 p.m. ET to discuss these results and provide an update on Enanta's research and development pipeline.
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals to Present at the Deutsche Bank 41st Annual Healthcare Conference Presentation to be Webcast on May 4, 2016 at 8:00 A.M. ET
BusinessWire - Tue Apr 26, 7:00AM CDT
Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will make a formal presentation session to investors at the Deutsche Bank 41st Annual Healthcare Conference on May 4, 2016 at 8:00 a.m. ET.
ENTA: 22.02 (+0.03)
Enanta Announces U.S. FDA has Approved AbbVie's Supplemental New Drug Application for Use of VIEKIRA PAK(R) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
BusinessWire - Mon Apr 25, 8:10AM CDT
--Supplemental New Drug Application was previously granted priority review designation by the FDA
ENTA: 22.02 (+0.03)
AbbVie Receives U.S. FDA Approval of Supplemental New Drug Application for VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without Ribavirin in Genotype 1b Chronic Hepatitis C Patients with Compensated Cirrhosis
PR Newswire - Mon Apr 25, 8:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for the use of VIEKIRA PAK® (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) without ribavirin (RBV) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection and compensated cirrhosis (Child-Pugh A). The application was previously granted priority review by the FDA, a designation given to investigational therapies that treat a serious condition and provide a significant improvement in safety or effectiveness.
ABBV: 64.03 (-0.07), ENTA: 22.02 (+0.03)
Enanta Announces New Data from AbbVie's SURVEYOR-1 and SURVEYOR-2 Studies Showing High Sustained Virologic Response Rates after 8 or 12 Weeks of Treatment in Patients with any of Genotypes 1 through 6 of Hepatitis C Virus
BusinessWire - Sat Apr 16, 12:10AM CDT
--100 percent SVR12 achieved with 12 weeks of treatment in difficult-to-treat genotype 3 patients with compensated cirrhosis (Child-Pugh A) new to therapy (3)
ENTA: 22.02 (+0.03)
Enanta Announces that AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
BusinessWire - Fri Apr 15, 12:15AM CDT
--91 percent achieved SVR12 with RBV in the primary intent-to-treat analysis; 86 percent achieved SVR12 without RBV
ENTA: 22.02 (+0.03)
AbbVie Announces Real-World Data with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) from Large German Hepatitis C-Registry
PR Newswire - Fri Apr 15, 12:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced new real-world data showing 96 percent of genotype 1 (GT1) patients (n=486/505 assessable for analysis) and 100 percent (n=53/53) of genotype 4 (GT4) patients achieved sustained virologic response at 12 weeks post-treatment (SVR12).1 These data support results seen in Phase 3 clinical trials for chronic GT1 or GT4 hepatitis C virus (HCV) infected patients treated with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) with or without ribavirin (RBV).
ABBV: 64.03 (-0.07), ENTA: 22.02 (+0.03)
AbbVie's Investigational, Pan-Genotypic Regimen of ABT-493 and ABT-530 Shows High SVR Rates in Genotype 1 Hepatitis C Patients Who Failed Previous Therapy with Direct-Acting Antivirals
PR Newswire - Fri Apr 15, 12:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 91 percent (n=20/22) of genotype 1 (GT1) chronic hepatitis C virus (HCV) infected patients who failed previous therapy with direct-acting antivirals (DAAs) achieved SVR12 with 12 weeks of ABT-493 and ABT-530 with ribavirin (RBV) in the primary intent-to-treat analysis. Additionally, 86 percent (n=19/22) of GT1 patients who received ABT-493 and ABT-530 without RBV, achieved SVR12.1 SVR12 was achieved in 95 percent of patients with and without RBV (n=20/21, n=19/20; respectively) in a modified intent-to-treat analysis, excluding patients who did not achieve SVR for reasons other than virologic failure.
ABBV: 64.03 (-0.07), ENTA: 22.02 (+0.03)
Enanta Announces High SVR Rates with AbbVie's VIEKIRAX(R) + EXVIERA(R) Regardless of the Presence of Resistance-Associated Variants Prior to Treatment in Genotype 1 Chronic Hepatitis C Patients
BusinessWire - Thu Apr 14, 7:22PM CDT
--97 percent of genotype 1a (GT1a) patients, with or without baseline NS5A RAVs, who received the regimen with ribavirin achieved SVR12(1)
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals Announces HCV Data Presentations at The International Liver Congress(TM) 2016
BusinessWire - Wed Mar 30, 6:07AM CDT
--New data to be presented on AbbVie's investigational, pan-genotypic regimen consisting of ABT-493, Enanta's second protease inhibitor, in combination with ABT-530, AbbVie's NS5A inhibitor
ENTA: 22.02 (+0.03)
AbbVie to Present Data on VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets) and Investigational, Pan-Genotypic Regimen at The International Liver Congress(TM) 2016
PR Newswire - Wed Mar 30, 6:00AM CDT
AbbVie (NYSE: ABBV), a global biopharmaceutical company, today announced that 25 abstracts have been accepted for presentation at The International Liver Congress(TM) (ILC) 2016 in Barcelona, Spain, April 13-17, including real-world data that support clinical trial results seen in AbbVie's development program with VIEKIRAX® (ombitasvir/paritaprevir/ritonavir tablets) and EXVIERA® (dasabuvir tablets). Abstracts presented will further expand scientific knowledge of VIEKIRAX and EXVIERA in genotype 1 (GT1) and genotype 4 (GT4) chronic hepatitis C virus (HCV) infected patients, including those with compensated cirrhosis (Child-Pugh A).
ABBV: 64.03 (-0.07), ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals beats 1Q profit forecasts
Automated Insights - Mon Feb 08, 3:14PM CST
WATERTOWN, Mass. (AP) _ Enanta Pharmaceuticals Inc. (ENTA) on Monday reported fiscal first-quarter earnings of $26.2 million.
ENTA: 22.02 (+0.03)
Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2015
BusinessWire - Mon Feb 08, 3:02PM CST
--Royalty revenue for paritaprevir containing regimens was $17.9 million
ENTA: 22.02 (+0.03)
